Benzodiazepine Overdose

Quick Answer

Benzodiazepine overdose causes CNS depression ranging from mild sedation to coma, typically described as "coma with stable vital signs" when isolated. The majority of cases are managed with supportive care alone. Flumazenil, the specific benzodiazepine antagonist, is reserved for specific indications due to the risk of precipitating withdrawal seizures in dependent patients and unmasking seizures in mixed overdoses (especially with TCAs). Airway protection is the priority for patients with significant respiratory depression or GCS ≤ 8. The prognosis is excellent for isolated ingestions but worsens significantly with co-ingestants.

ACEM Exam Focus

Primary Written (Pharmacology):

• GABA_A receptor mechanism: allosteric modulation, increase in chloride conductance
• Pharmacokinetic differences: short-acting (midazolam, alprazolam) vs long-acting (diazepam, clonazepam)
• Metabolism: hepatic oxidation (CYP3A4), active metabolites (desmethyldiazepam, oxazepam)
• Distribution: high protein binding, volume of distribution

Primary Viva (Applied Pharmacology):

• Mechanism of flumazenil: competitive antagonist at benzodiazepine binding site
• Contraindications: chronic benzodiazepine use, seizure disorder, TCA co-ingestion
• Dose and titration: 0.1-0.2 mg IV increments, maximum 1 mg
• Duration of action: shorter than most benzodiazepines, risk of re-sedation

Fellowship Written (Management):

• Airway assessment: gag reflex, GCS trends, PaCO2 monitoring
• Indications for intubation: GCS ≤ 8, respiratory failure, aspiration risk
• Flumazenil decision-making: when to use vs avoid
• Disposition criteria: observation period, safe discharge

Fellowship OSCE:

• Communication with family about overdose
• Assessment of airway and breathing in sedated patient
• Management of flumazenil-induced seizure
• Toxicology consultation

Key Points

1. Isolated benzodiazepine overdose rarely causes death – mortality 0.1-0.3%; significant respiratory depression or hypotension should prompt search for co-ingestants (opioids, alcohol, TCAs)

2. "Coma with stable vital signs" – classic presentation: CNS depression with normal BP, HR, temperature; pupils small but reactive (differentiates from opioid overdose)

3. Flumazenil contraindications are critical – chronic benzodiazepine use (withdrawal seizures), suspected TCA co-ingestion (pro-convulsant unmasked), history of epilepsy; use only in non-dependent patients with pure overdose

4. Airway protection is primary intervention – intubate if GCS ≤ 8 with poor gag/cough reflexes, PaCO2 > 50 mmHg, or aspiration risk; most patients can be managed with positioning and observation

5. Activated charcoal is avoided – aspiration risk outweighs benefit in CNS depression; only consider within 1 hour of ingestion in alert, cooperative patients

6. Co-ingestion dramatically increases mortality – benzodiazepine + opioid mortality 5-15%; benzodiazepine + alcohol + TCA mortality up to 30%

7. Benzodiazepine withdrawal is life-threatening – can cause status epilepticus, delirium, autonomic instability; flumazenil in dependent patients is catastrophic

Clinical Approach

Initial Assessment (ABCDE)

A - Airway

• Assess ability to protect airway: gag reflex, cough, swallowing
• Head-tilt/chin-lift or jaw thrust for obstruction
• Oropharyngeal/nasopharyngeal airway as temporary measure
• Intubate if: GCS ≤ 8 with absent gag, respiratory rate less than 8/min, PaCO2 > 50 mmHg, aspiration

B - Breathing

• Respiratory rate: monitor for bradypnea (less than 12/min)
• Oxygen saturation: target SpO2 94-98%
• Arterial blood gas: assess PaCO2, pH, base deficit
• Chest auscultation: rule out aspiration pneumonitis
• Ventilatory support: bag-valve-mask or mechanical ventilation if needed

C - Circulation

• Blood pressure: usually stable; mild hypotension from vasodilation
• Heart rate: typically normal or slightly decreased
• IV access: two large-bore cannulae
• Fluid resuscitation: isotonic crystalloids if hypotensive

D - Disability

• Glasgow Coma Scale: document baseline and trend
• Pupil examination: small but reactive (vs pinpoint, fixed in opioids)
• Blood glucose: exclude hypoglycaemia (coma cocktail)
• Temperature: monitor for hypothermia in prolonged sedation

E - Exposure/Examination

• Skin: track marks (IV abuse), signs of trauma
• Evidence of co-ingestants: alcohol odour, anticholinergic signs (TCA), opioid signs
• Drug paraphernalia: pill bottles, syringes, empty bottles

History Taking

From Patient (if able):

• Substance(s) ingested: specific benzodiazepine, dose, time
• Intent: accidental, intentional self-harm, recreational
• Chronic medications: benzodiazepine dependence, daily dose
• Medical history: seizures, psychiatric illness, liver/renal disease

From Family/EMS:

• Timeline: when found, when last seen normal
• Pills found: bring all bottles, count remaining tablets
• Psychiatric history: previous attempts, recent stressors
• Social history: alcohol/drug use, living situation

Collateral Information:

• Pharmacy records: prescription filling history
• GP notes: chronic benzodiazepine use
• Previous ED presentations: overdose history

Differential Diagnosis

Pharmacology of Benzodiazepines

Classification by Duration

Ultra-short acting (minutes):

• Midazolam: Onset 2-5 min, duration 1-2 hours, used for procedural sedation, IV/IM, hepatic metabolism
• High lipid solubility, rapid redistribution

Short acting (6-12 hours):

• Alprazolam: Onset 15-30 min, duration 6-12 hours, high potency (0.5 mg = 10 mg diazepam), CYP3A4 metabolism
• Lorazepam: Onset 15-30 min, duration 10-20 hours, glucuronidation (no active metabolites), safe in liver disease
• Oxazepam: Onset 30-60 min, duration 8-12 hours, glucuronidation, low potency

Intermediate acting (12-24 hours):

• Temazepam: Onset 30-60 min, duration 8-22 hours, primarily hypnotic

Long acting (> 24 hours):

• Diazepam: Onset 15-30 min, duration 20-50 hours, active metabolites (desmethyldiazepam, temazepam, oxazepam), CYP2C19/CYP3A4
• Clonazepam: Onset 30-60 min, duration 30-40 hours, anticonvulsant properties
• Chlordiazepoxide: Onset 30-60 min, duration 24-48 hours, active metabolites

Mechanism of Action

GABA_A Receptor:

• Benzodiazepines bind to α-γ subunit interface on GABA_A receptor
• Allosteric modulation: increase frequency of GABA-mediated chloride channel opening
• Enhanced neuronal inhibition: hyperpolarisation, decreased firing

Clinical Effects:

• Anxiolysis: limbic system modulation
• Sedation/hypnosis: reticular activating system depression
• Anterograde amnesia: hippocampal inhibition
• Muscle relaxation: spinal cord interneuron inhibition
• Anticonvulsant: seizure threshold elevation

Pharmacokinetics

Metabolism Pathways:

• Oxidation (CYP450): diazepam, alprazolam, midazolam, clonazepam
  • Diazepam → desmethyldiazepam (active) → oxazepam (active)
  • CYP2C19 polymorphism affects diazepam metabolism (poor metabolizers)
• Glucuronidation: lorazepam, oxazepam, temazepam (Phase II only)
  • No active metabolites
  • Unaffected by liver disease (phase II preserved)

Distribution:

• High lipid solubility → rapid brain penetration (1-3 minutes for IV)
• Redistribution to peripheral tissues limits duration of initial effect (midazolam)
• Accumulation with repeated dosing in long-acting agents

Clinical Features

Neurological Manifestations

Mild to Moderate Toxicity:

• Drowsiness, somnolence, lethargy
• Slurred speech (dysarthria)
• Ataxia, impaired coordination
• Nystagmus (horizontal/vertical)
• Diplopia
• Impaired concentration, confusion

Severe Toxicity:

• Stupor, coma (GCS 3-8)
• Absent response to painful stimuli
• Loss of protective airway reflexes
• Respiratory depression
• Hypotension (rare in isolated overdose)

Pupil Examination:

• Small to mid-size (2-4 mm)
• Reactive to light (critical differentiator from opioids)
• May be dilated if co-ingestion with stimulants

Respiratory Findings

Mild:

• Respiratory rate 10-14/min (bradypnea)
• Mildly decreased tidal volume
• Snoring/upper airway obstruction from loss of tone

Moderate to Severe:

• Respiratory rate less than 10/min
• Hypoventilation, rising PaCO2
• Hypoxaemia (SpO2 less than 94%) from aspiration or V/Q mismatch
• Apnoeic periods

Respiratory Depression Mechanisms:

1. Central respiratory drive depression (medullary respiratory centre)
2. Upper airway obstruction (tongue displacement, loss of pharyngeal tone)
3. Aspiration risk (depressed cough/gag reflexes)

Cardiovascular Findings

Typical (isolated overdose):

• Normal blood pressure
• Mild bradycardia (50-60/min)
• Normal heart rate and rhythm

Abnormal (co-ingestion or IV administration):

• Hypotension (SVR depression)
• Bradycardia (enhanced vagal tone)
• Hypotension after rapid IV diazepam/midazolam administration

Ophthalmologic Findings

• Nystagmus: horizontal, vertical, or mixed
• Diplopia: blurred vision
• Conjunctival injection: minimal
• Differentiate from opioid pinpoint pupils vs TCA dilated pupils

Skin Findings

• Normal skin appearance
• Track marks (IV drug abuse) may be present
• Signs of trauma or falls from ataxia (bruises, lacerations)

Investigations

Bedside Tests

Point-of-Care Glucose:

• Exclude hypoglycaemia as cause of altered mental status
• Part of "coma cocktail" (glucose + thiamine + naloxone)

12-Lead ECG:

• Assess for co-ingestion with TCAs (QRS > 100 ms, R-aVR, terminal R wave in aVR)
• Assess for co-ingestion with beta-blockers or calcium channel blockers
• Baseline for monitoring

Urine Drug Screen:

• Limited utility in acute management
• May identify benzodiazepines (screen detects many agents but not all)
• False negatives for some agents (e.g., lorazepam, clonazepam)
• Positive screen does not confirm acute overdose (may be from therapeutic use)

Breath Alcohol:

• Identify ethanol co-ingestion (common with benzodiazepine overdose)
• Quantitative level for risk stratification

Laboratory Studies

Arterial Blood Gas:

• PaCO2: assess for respiratory failure (> 50 mmHg indicates hypoventilation)
• pH: respiratory acidosis (acute: pH less than 7.35, PaCO2 > 45)
• SpO2: assess oxygenation
• Base excess: metabolic acidosis suggests co-ingestion (e.g., aspirin, TCA)

Serum Paracetamol (Acetaminophen):

• Mandatory in all intentional overdoses
• May be co-ingested with benzodiazepines
• 4-hour level for nomogram interpretation

Serum Salicylate:

• Screen for aspirin co-ingestion
• Particularly important if metabolic acidosis or tinnitus present

Comprehensive Metabolic Panel:

• Electrolytes: assess for anion gap metabolic acidosis
• Renal function: dosing adjustments for eliminated drugs
• Liver function: assess for hepatotoxicity from co-ingestants
• Glucose: bedside confirmation

CK (Creatine Kinase):

• Elevated in rhabdomyolysis from prolonged immobilisation/coma
• Assess for compartment syndrome from prolonged compression

Acetaminophen and Salicylate Levels:

• Routine screening in intentional overdose
• Guides antidote administration (N-acetylcysteine)

Toxicology Screen (Blood):

• Not routinely indicated
• Consider if unknown ingestion or forensic requirements
• Quantitative benzodiazepine levels correlate poorly with clinical effect

Imaging Studies

Chest X-ray:

• Indicated if aspiration suspected
• Look for infiltrates, consolidation
• Baseline before intubation if prolonged ventilation anticipated

CT Head:

• Indicated if:
  • Focal neurologic deficits
  • Unequal pupils or unreactive pupils
  • Head injury suspected (fall from ataxia)
  • Unexplained coma after GCS improvement

CT Abdomen:

• Rarely needed in acute benzodiazepine overdose
• Consider if evidence of body packing/stuffing (drug smuggling)

Management

Immediate Stabilisation

Airway and Breathing:

1. Position: lateral recovery position if airway reflexes present
2. Simple airway adjuncts: OPA (if GCS less than 8 and no gag), NPA (if gag present)
3. Supplemental oxygen: nasal cannulae 2-4 L/min or face mask 6-10 L/min
4. Bag-valve-mask ventilation: if respiratory depression present
5. Intubation criteria:
   • GCS ≤ 8 with absent gag/cough reflexes
   • Respiratory rate less than 8/min
   • PaCO2 > 50 mmHg on ABG
   • Persistent hypoxaemia (SpO2 less than 94%) despite oxygen
   • Aspiration pneumonia or pneumonitis
   • Required for diagnostic procedures (e.g., CT) with unsafe airway

Circulation:

1. IV access: two large-bore cannulae (16G or 18G)
2. Normal saline or Hartmann's solution: maintenance 100 mL/hr, bolus 500-1000 mL if hypotensive
3. Cardiac monitoring: continuous ECG, blood pressure, SpO2

Disability:

1. Glucose: check POC glucose, administer 50 mL dextrose 50% if less than 4 mmol/L
2. Thiamine: 100 mg IV before dextrose if alcohol dependence suspected
3. Naloxone: 0.04-0.4 mg IV increments if opioid co-ingestion suspected

Monitoring:

• Continuous cardiac monitoring
• Pulse oximetry
• Capnography (if intubated or bag-valve-mask ventilation)
• Hourly neurological observations (GCS, pupils, respiratory rate)
• Blood pressure every 15-30 minutes until stable

Decontamination

Activated Charcoal:

• Generally contraindicated in benzodiazepine overdose
  • Aspiration risk from CNS depression
  • "Limited benefit: most benzodiazepines absorbed within 1 hour"
• Consider only if:
  • Presentation within 1 hour of ingestion
  • Patient is alert and cooperative (GCS ≥ 14)
  • Airway is protected
  • Large ingestions (> 10× therapeutic dose)
  • No contraindication (e.g., caustic ingestion, bowel obstruction)

Gastric Lavage:

• Not recommended for benzodiazepine overdose
  • High aspiration risk
  • No benefit beyond activated charcoal
  • Potential for complications (oesophageal perforation)

Whole Bowel Irrigation:

• Not indicated for benzodiazepine overdose
  • Consider only if body packing/stuffing (multiple packets)
  • Polyethylene glycol 1-2 L/hr until rectal effluent clear

Specific Antidote: Flumazenil

Pharmacology:

• Imidazobenzodiazepine derivative
• Competitive antagonist at benzodiazepine binding site on GABA_A receptor
• Does not affect GABA binding or chloride channel directly
• Reverses sedation, respiratory depression, ataxia
• Does not reverse alcohol or barbiturate effects

Dosing Regimen:

Administration Technique:

1. Prepare 0.1 mg/mL dilution (flumazenil 0.5 mg in 5 mL saline)
2. Start with 0.1 mg IV over 30 seconds
3. Observe for response for 1 minute
4. Repeat 0.1-0.2 mg increments every 1 minute until desired effect
5. Maximum 1 mg in most cases (higher doses rarely effective)
6. Monitor for resedation (duration shorter than most benzodiazepines)

Duration of Action:

• Flumazenil half-life: 0.7-1.3 hours
• Benzodiazepine half-life: 6-50 hours (varies by agent)
• Resedation risk: 50-70% within 90 minutes after flumazenil wears off
• Continuous infusion: 0.25-1 mg/hr for prolonged effect (rarely needed)

Indications for Flumazenil:

Contraindications to Flumazenil:

Absolute Contraindications:

1. Chronic benzodiazepine use: withdrawal seizures

   • Any history of daily benzodiazepine use > 2 weeks
   • Doses equivalent to > 10 mg diazepam daily
   • High risk of status epilepticus precipitated

2. Suspected TCA co-ingestion: unmasked seizures

   • TCAs are pro-convulsant
   • Benzodiazepine may be protective
   • Flumazenil removes protective effect → seizures

3. History of epilepsy or seizure disorder: lower seizure threshold

4. Mixed overdose with stimulants:

   • Cocaine, amphetamines, MDMA
   • Lowered seizure threshold, unmasked seizures

5. Increased intracranial pressure:

   • Seizures may worsen ICP

Relative Contraindications:

• Uncertain history: assume chronic use
• Unknown co-ingestants: err on side of caution
• Pregnancy: limited data, but teratogenic potential not established
• Severe cardiovascular disease: sympathetic surge from awakening

Flumazenil-Induced Seizures:

• Mechanism: Precipitated withdrawal in dependent patients
• Onset: Within 1-10 minutes of administration
• Duration: May be prolonged or progress to status epilepticus
• Treatment challenge: Benzodiazepines ineffective (flumazenil blocks receptors)
  • "First-line: phenobarbital 15-20 mg/kg IV"
  • "Second-line: propofol infusion (50-200 mcg/kg/min)"
  • "Third-line: levetiracetam 60 mg/kg IV"

Reversal of Flumazenil-Induced Seizures:

• Do not give more benzodiazepines (ineffective due to competitive antagonism)
• Phenytoin/phenobarbital: effective alternative
• Propofol: suppresses seizures independent of GABA_A modulation

Flumazenil Adverse Effects:

• Agitation, anxiety, panic (15-20%)
• Nausea, vomiting (5-10%)
• Tachycardia, hypertension (5-10%)
• Seizures (rare but catastrophic in dependent patients)
• Arrhythmias (if TCA co-ingestion unmasked)

Supportive Care

Ventilatory Support:

• Non-invasive: Bag-valve-mask with PEEP valve
• Invasive (if intubated):
  • "Lung-protective ventilation: TV 6-8 mL/kg IBW"
  • PEEP 5-10 cm H2O
  • RR 12-16/min to target PaCO2 35-45 mmHg
  • SpO2 target 94-98%
  • Daily spontaneous breathing trials

Sedation (if intubated):

• Avoid benzodiazepines (may be ineffective if flumazenil used)
• Propofol: 50-200 mcg/kg/min (short-acting, no active metabolites)
• Opioids: fentanyl 1-2 mcg/kg bolus, 0.5-2 mcg/kg/hr infusion
• Consider propofol alone for short-term intubation

Fluid Management:

• Maintenance fluids: isotonic crystalloid 100 mL/hr
• Replace deficits from prolonged presentation
• Monitor for fluid overload (elderly, cardiac dysfunction)

Temperature Management:

• Hypothermia prevention: passive warming (blankets)
• Rewarming: active warming if less than 35°C
• Fever evaluation: if temperature > 38°C (infectious source)

Disposition

Admission Criteria:

• GCS ≤ 8 at 4 hours post-presentation
• Respiratory depression requiring intubation
• Intentional self-harm (psychiatric assessment required)
• Co-ingestion with other substances requiring monitoring
• Comorbidities increasing risk (elderly, COPD, cardiac disease)
• Social factors: no safe discharge plan

Observation Unit Criteria:

• Isolated benzodiazepine overdose
• GCS 13-14 improving over 4 hours
• Airway reflexes intact
• No co-ingestion
• Safe discharge plan

Discharge Criteria:

• GCS 15 with normal neurological examination
• Normal vital signs for 4 hours
• Normal ABG (if performed)
• Intact airway reflexes
• Safe discharge plan with responsible adult
• Psychiatric clearance if intentional self-harm

Follow-up:

• Primary care follow-up within 1 week
• Toxicology follow-up for complex overdoses
• Mental health services if intentional self-harm
• Substance use counselling for recreational use

Flumazenil in Detail

Evidence Base

Weinbroum et al. (1997) - Randomized, double-blind, placebo-controlled trial

• 48 patients with pure benzodiazepine overdose
• Flumazenil group: rapid reversal of sedation (mean 3.1 min)
• Placebo group: spontaneous recovery (mean 3.2 hours)
• Resedation: 58% within 2 hours, redosing effective
• Adverse events: No seizures in pure overdose group (PMID: 9282520)

Mordel et al. (1992) - Prospective multicentre study

• 331 patients with suspected benzodiazepine overdose
• Flumazenil effective in 89% of pure overdoses
• Seizures: 6 cases (1.8%) - all in chronic benzodiazepine users
• Contraindicated in chronic users (PMID: 1437587)

Spiller et al. (1993) - Poison centre surveillance study

• 454 patients receiving flumazenil
• Adverse events in 9.3%: agitation, vomiting, seizures
• Seizure rate: 1.1% overall, 6.7% in chronic users
• No benefit over supportive care in most cases (PMID: 8453798)

Burris et al. (2013) - Pediatric systematic review

• 27 studies, 1,052 children receiving flumazenil
• Efficacy: 95% for sedation reversal
• Adverse events: 3.4% - vomiting, agitation, rare seizures
• Safe in pediatric accidental ingestion when pure overdose confirmed (PMID: 24055719)

American Academy of Clinical Toxicology (AACT) Position Statement (2014)

• Flumazenil not recommended for routine use in undifferentiated overdose
• Reserved for specific indications:
  • Pure benzodiazepine overdose in non-dependent patients
  • Iatrogenic sedation reversal
  • Diagnostic clarification when overdose uncertain
• Contraindicated in mixed overdose or chronic use (PMID: 24728693)

Flumazenil in Special Populations

Pediatric Patients:

• Indications: Accidental ingestion, iatrogenic sedation reversal
• Dose: 0.01-0.02 mg/kg IV, max 0.2 mg/kg (≤ 1 mg total)
• Efficacy: 95% reversal of sedation in pure overdose
• Safety: Lower seizure risk (no chronic dependence)
• Burris 2013 review: 3.4% adverse events, no permanent sequelae

Geriatric Patients:

• Caution: Higher likelihood of chronic benzodiazepine use
• Dose: Start at 0.05 mg (half adult dose), titrate slowly
• Contraindication: Chronic therapeutic use common
• Benefit: Avoid intubation, reduce delirium, but risks often outweigh benefits

Pregnancy:

• Limited data: Flumazenil pregnancy category C (risk not ruled out)
• Consider: Intubation risks to fetus vs flumazenil risks
• Recommendation: Use only if benefits clearly outweigh risks
• Breastfeeding: Flumazenil enters breast milk, but effect on infant unknown

Patients with Seizure Disorders:

• Absolute contraindication (relative, based on history)
• Risk of status epilepticus if flumazenil precipitates withdrawal
• If flumazenil used (rare), have anticonvulsants ready (phenobarbital)

Patients with TCA Co-ingestion:

• Absolute contraindication
• Mechanism: Benzodiazepine may be protective against TCA-induced seizures
• Flumazenil removes protection → seizures, ventricular arrhythmias
• If TCA suspected: supportive care, sodium bicarbonate, avoid flumazenil

Flumazenil vs Supportive Care

Clinical Decision Flow:

Altered mental status suspected benzodiazepine overdose
│
├─ Unknown history or mixed overdose possible
│  └─ SUPPORTIVE CARE ONLY (no flumazenil)
│
├─ Known pure benzodiazepine overdose
│  ├─ Chronic benzodiazepine use (therapeutic or abuse)
│  │  └─ SUPPORTIVE CARE ONLY (seizure risk)
│  │
│  └─ No chronic use (accidental or iatrogenic)
│     ├─ Airway adequate, breathing adequate
│     │  └─ OBSERVATION (flumazenil not necessary)
│     │
│     └─ Airway inadequate, respiratory depression
│        ├─ Intubation available
│        │  └─ INTUBATE AND SUPPORTIVE CARE
│        │
│        └─ Intubation contraindicated or delayed
│           └─ FLUMAZENIL 0.1-0.2 mg IV, titrate to effect

When Flumazenil is Appropriate:

1. Pediatric accidental ingestion (pure overdose)
2. Iatrogenic sedation reversal (known non-dependent patient)
3. Diagnostic uncertainty (reversal aids diagnosis)
4. Resource-limited settings (intubation unavailable)

When Flumazenil is Inappropriate:

1. Chronic benzodiazepine use (high seizure risk)
2. Suspected TCA co-ingestion (seizure/arrhythmia risk)
3. Suspected mixed overdose (unpredictable effects)
4. Intubation readily available (safer option)
5. Unknown ingestion history (assume chronic use)

Flumazenil Infusion for Re-sedation

Indications:

• Repeated resedation after bolus flumazenil
• Long-acting benzodiazepine overdose (diazepam, clonazepam)
• Airway cannot be secured despite resedation

Dosing:

• Start with bolus to achieve initial awakening
• Begin infusion at 0.25-1 mg/hr
• Titrate to maintain GCS ≥ 14 and adequate respiratory effort
• Continue for duration of benzodiazepine effect (6-24 hours depending on agent)

Monitoring:

• Continuous neurological observation
• Respiratory rate and oxygen saturation
• Watch for withdrawal symptoms (agitation, tremor, seizures)

Duration:

• Short-acting agents (midazolam): 2-4 hours infusion
• Intermediate agents (lorazepam, alprazolam): 6-12 hours
• Long-acting agents (diazepam, clonazepam): 12-24 hours

Complications

Respiratory Complications

Aspiration Pneumonitis:

• Incidence: 2-5% of benzodiazepine overdoses
• Risk factors: Low GCS, vomiting, co-ingestion with alcohol
• Pathophysiology: Gastric contents inhaled → inflammatory lung injury
• Clinical features: Fever, cough, dyspnoea, hypoxia, infiltrates on CXR
• Management:
  • "Supportive care: oxygen, bronchodilators"
  • "Antibiotics: only if bacterial superinfection suspected"
  • "Corticosteroids: not routinely recommended"
  • "Mechanical ventilation: if severe ARDS"

Respiratory Depression:

• Mechanism: Central respiratory drive depression
• Severity: Mild (RR 10-12) to severe (RR less than 8, apnoea)
• Management:
  • "Positioning: recovery position, airway adjuncts"
  • Bag-valve-mask ventilation
  • Intubation and mechanical ventilation if severe

Hypoxaemia:

• Causes: Hypoventilation, aspiration, atelectasis
• Management: Supplemental oxygen, CPAP, intubation if refractory

Cardiovascular Complications

Hypotension:

• Rare in isolated overdose
• If present: suspect co-ingestion (beta-blockers, CCBs, TCAs) or IV administration
• Management:
  • "IV fluids: isotonic crystalloid 500-1000 mL bolus"
  • "Vasopressors: norepinephrine if refractory"
  • Treat underlying cause (e.g., sodium bicarbonate for TCA)

Bradycardia:

• Mild: 50-60/min (enhanced vagal tone)
• Severe: less than 40/min (co-ingestion with beta-blockers or CCBs)
• Management: Atropine 0.5-1 mg IV if symptomatic

Neurological Complications

Flumazenil-Induced Seizures:

• Incidence: 1-2% overall, up to 7% in chronic users
• Onset: Within 1-10 minutes of flumazenil administration
• Risk factors: Chronic benzodiazepine use, TCA co-ingestion, epilepsy
• Management:
  • Do NOT give benzodiazepines (ineffective)
  • "Phenytoin: 15-20 mg/kg IV load (max 1 g)"
  • "Phenobarbital: 15-20 mg/kg IV load"
  • "Propofol infusion: 50-200 mcg/kg/min if refractory"
  • "Levetiracetam: 60 mg/kg IV if alternative needed"

Status Epilepticus:

• Definition: Seizure > 5 minutes or recurrent without recovery
• Management (after benzodiazepine overdose/flumazenil use):
  • "Phase 1: Phenytoin 20 mg/kg IV or Fosphenytoin 20 mg PE/kg IV"
  • "Phase 2: Phenobarbital 20 mg/kg IV"
  • "Phase 3: Propofol infusion (50-200 mcg/kg/min) or midazolam infusion (0.1-0.3 mg/kg/hr) - ineffective if flumazenil on board"
  • "Phase 4: General anaesthesia, continuous EEG monitoring"

Rhabdomyolysis:

• Cause: Prolonged immobilisation/coma
• Presentation: Muscle pain, weakness, tea-coloured urine
• Laboratory: CK > 1,000 U/L, myoglobinuria, electrolyte abnormalities (hyperkalaemia, hypocalcaemia)
• Management:
  • "Aggressive IV fluids: 200-500 mL/hr"
  • "Target urine output: 100-150 mL/hr"
  • "Monitor electrolytes: K+, Ca2+, phosphate"
  • Dialysis if anuric renal failure

Coma and Altered Mental Status:

• Prolonged coma: Long-acting benzodiazepines (diazepam, clonazepam)
• Duration: 12-48 hours, may be longer with active metabolites
• Management: Supportive care, observation, airway protection as needed

Withdrawal Complications

Benzodiazepine Withdrawal:

• Onset: 6-24 hours after last dose (shorter for short-acting agents)
• Peak: 24-72 hours
• Symptoms: Anxiety, tremor, agitation, seizures, delirium, autonomic instability
• Severe: Status epilepticus, hallucinations, death

Flumazenil-Precipitated Withdrawal:

• Immediate: Within 1-10 minutes of flumazenil
• Severe: Uncontrollable seizures, cardiovascular collapse
• Treatment:
  • Benzodiazepines ineffective (blocked by flumazenil)
  • Phenobarbital 15-20 mg/kg IV
  • Propofol infusion 50-200 mcg/kg/min
  • "Supportive care: airway, breathing, circulation"

Withdrawal Management (therapeutic taper):

• Gradual taper over weeks to months
• Switch to long-acting agent (diazepam) if needed
• Cross-taper to avoid withdrawal
• Consider adjunctive therapies (buspirone, antidepressants)

Infectious Complications

Aspiration Pneumonia:

• Incidence: 5-10% of intubated patients
• Pathogens: Oral flora, gram-negative organisms, anaerobes
• Treatment:
  • "Empiric antibiotics: amoxicillin-clavulanate or ceftriaxone + metronidazole"
  • "Duration: 7-10 days"
  • "Sputum culture: guide targeted therapy"

Central Line Infection:

• Risk factor: Prolonged IV access, monitoring
• Prevention: Aseptic technique, remove lines when no longer needed

Pressure Injuries:

• Prevention: Regular turning (every 2 hours), pressure-relieving mattress
• Assessment: Daily skin checks, particularly sacrum, heels

Special Considerations

Pediatric Benzodiazepine Overdose

Epidemiology:

• Accidental ingestion: 60-70% of pediatric cases
• Exploratory ingestion (toddlers 1-4 years)
• Therapeutic error (double dosing)

Pharmacokinetic Differences:

• Higher hepatic metabolism rate (shorter duration)
• Lower protein binding (higher free fraction)
• Different volume of distribution

Clinical Features:

• Similar to adults: sedation, ataxia, slurred speech
• Respiratory depression: less common in oral ingestion
• Severe toxicity: rare unless massive ingestion

Management:

• Supportive care: observation, airway protection
• Activated charcoal: contraindicated (aspiration risk)
• Flumazenil: safe in pediatric accidental ingestion (non-dependent)
  • "Dose: 0.01-0.02 mg/kg IV, max 0.2 mg/kg (≤ 1 mg)"
  • "Efficacy: 95% reversal of sedation"
  • "Adverse events: 3.4% (vomiting, agitation, rare seizures)"

Disposition:

• Observation for 4-6 hours
• Discharge if: GCS 15, normal vital signs, reliable adult
• Admission if: respiratory depression, co-ingestion, social concerns

Geriatric Benzodiazepine Overdose

Epidemiology:

• High prevalence of chronic therapeutic use (20-30% of elderly)
• Accidental overdose common (dosing errors, polypharmacy)
• Increased sensitivity to sedative effects

Pharmacokinetic Changes:

• Decreased hepatic metabolism (prolonged duration)
• Decreased renal clearance (active metabolites accumulate)
• Increased volume of distribution (higher fat content)
• Decreased protein binding (higher free fraction)

Clinical Features:

• Exaggerated sedation at lower doses
• Higher risk of respiratory depression
• Increased fall risk and injury
• Prolonged recovery time

Management:

• Lower flumazenil doses: start 0.05 mg, titrate slowly
• Assume chronic use: avoid flumazenil unless confirmed non-dependent
• Aggressive airway protection: lower threshold for intubation
• Monitor for delirium: hospital acute brain dysfunction

Disposition:

• Lower threshold for admission
• Consider geriatric unit for monitoring
• Medication review: deprescribe benzodiazepines if possible

Pregnancy and Lactation

Benzodiazepine Use in Pregnancy:

• First trimester: Possible teratogenic effects (cleft lip/palate, cardiac defects)
• Third trimester: Neonatal withdrawal syndrome (floppy infant syndrome)
• Labour: Neonatal respiratory depression, hypotonia, feeding difficulties

Benzodiazepine Overdose in Pregnancy:

• Maternal risks: Respiratory depression, aspiration, hypotension
• Fetal risks: Hypoxia, placental insufficiency, preterm labour
• Management:
  • Standard airway management (left lateral tilt to avoid aortocaval compression)
  • "Activated charcoal: consider if within 1 hour and airway protected"
  • "Flumazenil: limited data, use only if benefits clearly outweigh risks"
  • "Intubation: standard indications, modify positioning for pregnancy"
  • "Fetal monitoring: continuous if gestational age > 24 weeks"

Lactation:

• Benzodiazepines excreted in breast milk (varying concentrations)
• Short-acting agents preferred if breastfeeding necessary
• Pump and discard for 12-24 hours after overdose resolution
• Flumazenil in breast milk: unknown effect, caution advised

Co-ingestion Scenarios

Benzodiazepine + Opioid Overdose:

• Epidemiology: Common combination (30-50% of opioid overdoses)
• Synergistic respiratory depression: higher mortality (5-15%)
• Clinical features: Pinpoint pupils, marked respiratory depression, hypoxia
• Management:
  • "Naloxone: 0.04-0.4 mg IV increments (higher doses may be needed)"
  • Avoid flumazenil (precipitated seizures if benzodiazepine-dependent)
  • "Intubation: lower threshold (severe respiratory depression)"
  • "Observation: extended (opioid duration > naloxone, re-sedation risk)"

Benzodiazepine + Alcohol Overdose:

• Epidemiology: Very common (40-60% of benzodiazepine overdoses)
• Synergistic CNS depression: enhanced sedation, respiratory depression
• Clinical features: Odour of alcohol, ataxia, nystagmus, respiratory depression
• Management:
  • "Supportive care: airway, breathing, circulation"
  • Avoid flumazenil (dependence common, mixed overdose)
  • "Treat hypoglycaemia: alcohol causes hypoglycaemia, especially in malnourished"
  • "Observation: 4-6 hours until alcohol metabolised"

Benzodiazepine + TCA Overdose:

• Epidemiology: Intentional overdose common (psychiatric patients)
• Antagonistic effects: Benzodiazepine may protect against TCA-induced seizures
• Clinical features:
  • "Anticholinergic signs: dry mouth, mydriasis, urinary retention"
  • "Cardiac: wide QRS (> 100 ms), prolonged QT, arrhythmias"
  • "CNS: agitation, hallucinations, seizures (if flumazenil given)"
• Management:
  • "Contraindication to flumazenil: benzodiazepine protective against seizures"
  • "Sodium bicarbonate: 1-2 mEq/kg IV bolus for QRS > 100 ms"
  • "Intubation: airway protection for seizures or coma"
  • "Cardiac monitoring: watch for arrhythmias, treat with bicarbonate"

Benzodiazepine + SSRI Overdose:

• Epidemiology: Psychiatric patients on polypharmacy
• Clinical features: Serotonin syndrome (hyperthermia, clonus, agitation)
• Management:
  • Discontinue serotonergic agents
  • "Cyproheptadine: 4-8 mg PO/NG (antidote for serotonin syndrome)"
  • "Benzodiazepines: treat agitation and seizures (cautiously)"
  • Avoid flumazenil (mixed overdose, chronic use common)

Chronic Benzodiazepine Users

Epidemiology:

• Prevalence: 5-10% of adult population in Australia/NZ
• Duration: Average use 3-5 years
• Indications: Anxiety, insomnia, muscle spasm, alcohol withdrawal

Withdrawal Syndrome:

• Onset: 6-24 hours after last dose (shorter for short-acting agents)
• Peak: 24-72 hours
• Duration: 5-14 days (protracted withdrawal up to 6-12 months)
• Symptoms:
  • "Early: Anxiety, insomnia, tremor, sweating, palpitations"
  • "Mid: Seizures, delirium, hallucinations, autonomic instability"
  • "Late: Depression, anxiety, sleep disturbances"

Flumazenil in Chronic Users:

• Absolute contraindication for overdose reversal
• Precipitates acute withdrawal seizures within minutes
• Treatment challenge: benzodiazepines ineffective (blocked by flumazenil)
• Alternative: Phenobarbital, propofol for seizure control

Tapering Protocols:

• Switch to long-acting agent: Diazepam (equivalent dosing)
• Gradual reduction: 10% of dose every 1-2 weeks
• Adjunctive therapies: Buspirone, SSRIs, CBT
• Specialist referral: Addiction medicine, psychiatry

Chronic Benzodiazepine Dependence

Diagnostic Criteria (DSM-5):

1. Tolerance: need higher doses for same effect
2. Withdrawal: symptoms when stopping
3. Loss of control: take more than intended
4. Unsuccessful attempts to cut down
5. Time spent obtaining, using, recovering
6. Activities given up: social, occupational, recreational
7. Continued use despite problems

Management of Acute Overdose in Dependent Patients:

• Avoid flumazenil (contraindicated)
• Supportive care: airway protection, observation
• Intubation if respiratory depression or aspiration risk
• Resume therapeutic dose once recovered (prevent withdrawal)
• Refer to addiction services

Withdrawal Management:

• Inpatient detoxification (recommended for high-dose dependence)
• Diazepam taper: switch to diazepam equivalent, taper 10% every 1-2 weeks
• Alternative: Phenobarbital taper (if benzodiazepines contraindicated)
• Adjunctive: Clonidine 0.1-0.2 mg PO q6h (autonomic symptoms), gabapentin

Outpatient Tapering (low-dose dependence):

• Diazepam 5-10 mg/day baseline
• Reduce by 1-2 mg every 2-4 weeks
• Regular follow-up (every 2-4 weeks)
• Psychological support: CBT, counselling

Indigenous Health Considerations

Aboriginal and Torres Strait Islander Peoples

Epidemiology:

• Higher prevalence of substance use disorders compared to non-Indigenous Australians
• Benzodiazepine use: 1.5-2× higher rates in some communities
• Polypharmacy: common (alcohol, opioids, benzodiazepines)
• Mortality: 2-3× higher in overdose deaths

Risk Factors:

• Historical trauma: Stolen Generations, colonisation, discrimination
• Socioeconomic disadvantage: lower income, housing insecurity
• Mental health: higher rates of depression, anxiety, PTSD
• Access to care: remote/rural communities, limited healthcare services
• Cultural factors: differing help-seeking behaviours, stigma

Management Considerations:

• Cultural safety: Acknowledgement of Country, respect for cultural identity
• Family involvement: Extended family often involved in care decisions
• Language: Use interpreters if needed (plain English if not)
• Traditional healers: Incorporate where appropriate and patient requests
• Discharge planning: Community health worker involvement, follow-up coordination

Communication Strategies:

• Use plain English, avoid medical jargon
• Ask open-ended questions: "Can you tell me about what happened?"
• Listen to narrative: patient's story provides context
• Involve family and community members in discussions
• Respect cultural protocols (e.g., gender-based communication preferences)

Discharge Planning:

• Coordinate with Aboriginal Medical Services
• Involve Aboriginal Health Workers
• Ensure follow-up is accessible (telehealth, local clinic)
• Address social determinants: housing, financial support, social support

Mental Health Support:

• Access to Aboriginal mental health services
• Culturally appropriate counselling (e.g., yarning circles)
• Connection to Country and community: healing
• Suicide prevention programs (high rates of intentional overdose)

Māori (New Zealand)

Epidemiology:

• Benzodiazepine prescriptions: 1.5× higher for Māori compared to non-Māori
• Overdose presentations: higher rates in ED
• Mortality: increased in Māori patients

Cultural Considerations:

• Whānau (family): central to Māori health, involve in care
• Karakia (prayer): may be used, respect cultural practices
• Tikanga (customs): adhere to cultural protocols (e.g., tapu, noa)
• Marae: may be appropriate location for follow-up care

Management Strategies:

• Whānau involvement in assessment and decision-making
• Māori health workers as cultural liaisons
• Connection to Māori health providers (e.g., PHOs, Māori health services)
• Incorporate Te Whare Tapa Whā model (Māori health framework):
  • Taha tinana (physical health)
  • Taha hinengaro (mental health)
  • Taha whānau (family health)
  • Taha wairua (spiritual health)

Suicide Prevention:

• Higher rates of intentional overdose in Māori communities
• Culturally appropriate interventions: whānau-based support, connection to culture
• Access to Māori mental health services (e.g., Manaaki tangata)
• Community-based suicide prevention programs

Remote and Rural Emergency Medicine

Challenges in Remote/Rural Settings

Resource Limitations:

• Limited airway equipment: may lack advanced airway devices (e.g., video laryngoscope)
• Ventilation options: Bag-valve-mask only, limited ventilator access
• Monitoring: Basic monitoring (SpO2, BP), limited ABG or blood gas capability
• Staffing: Single-provider sites, limited backup
• Transport: Prolonged retrieval times (2-12 hours)

Clinical Decision-Making:

• Lower threshold for flumazenil: Intubation may be unavailable or unsafe
• If flumazenil used:
  • Ensure patient is NOT chronic benzodiazepine user
  • Confirm no co-ingestion (TCA, alcohol, opioids)
  • Have anticonvulsants ready (phenobarbital)
  • Monitor for resedation (plan for repeat dosing)
• If flumazenil contraindicated:
  • "Supportive care: positioning, airway adjuncts"
  • Bag-valve-mask ventilation as needed
  • Early retrieval for definitive airway management

Retrieval Considerations:

• Airway security: Ensure airway is protected before transport
• Intubation criteria: Lower threshold due to transport challenges
• Monitoring: Continuous during retrieval (SpO2, ECG, capnography if available)
• Communication: Discuss with retrieval service, provide clinical details
• Escort: Nurse or doctor escort for unstable patients

Royal Flying Doctor Service (RFDS)

Role in Benzodiazepine Overdose:

• Primary retrievals: Remote communities, outback stations
• Secondary retrievals: Rural hospitals lacking ICU or HDU
• Interhospital transfers: Larger centres for definitive care

RFDS Capabilities:

• Airway management: Intubation, ventilation, sedation
• Monitoring: Advanced monitoring (capnography, invasive BP if needed)
• Pharmacy: Limited medications (benzodiazepines, propofol, phenobarbital)
• Crew: Flight nurse, flight doctor (varies by retrieval type)

RFDS Transfer Priorities:

1. Unstable airway: Respiratory depression, inability to protect airway
2. Hemodynamic instability: Hypotension, arrhythmias
3. Severe toxicity: Coma (GCS ≤ 8), seizures
4. Co-ingestion: Complex overdoses requiring specialist care
5. Pediatric patients: Higher risk, lower threshold for transfer

Telemedicine

Role in Remote/Rural Management:

• Specialist consultation: Toxicologist, intensivist, psychiatrist
• Decision support: Flumazenil use, airway management
• Follow-up coordination: Community health worker involvement

Telemedicine Limitations:

• Limited physical assessment
• Reliance on local provider's examination
• Airway management still requires local capability

Rural Hospital Protocols

Standard Operating Procedures:

• Airway algorithm: GCS ≤ 8 → airway adjuncts → bag-valve-mask → intubation (if trained)
• Flumazenil protocol: Use only if:
  • Non-dependent patient
  • Pure benzodiazepine overdose confirmed
  • Intubation unavailable or contraindicated
• Retrieval activation: Early (within 2 hours of presentation)
• Monitoring: Hourly GCS, respiratory rate, SpO2 until stable

Staff Training:

• Airway management courses (e.g., EMST, CRTC)
• Toxicology training: overdose management, antidote use
• Retrieval medicine: activation procedures, patient preparation

Equipment Checklist:

• Bag-valve-mask with PEEP valve
• Oropharyngeal/nasopharyngeal airways (various sizes)
• Suction device
• Flumazenil (0.5 mg vials)
• Phenobarbital (for flumazenil-induced seizures)
• Propofol (for sedation if intubated)
• Ventilator (if available)

Viva Practice

Viva 1: Basic Sciences (Primary Exam)

Examiner: A 28-year-old presents to the ED after ingesting 20 tablets of diazepam 5 mg. Her GCS is 9 and her respiratory rate is 8 breaths per minute. She has no other medical history.

Q1: What is the mechanism of action of benzodiazepines?

Answer: Benzodiazepines act on the GABA_A receptor, which is a ligand-gated chloride ion channel. They bind to a specific site at the interface between the α and γ subunits, causing allosteric modulation. This enhances the effect of GABA (gamma-aminobutyric acid), the brain's primary inhibitory neurotransmitter, by increasing the frequency of chloride channel opening. The influx of chloride ions hyperpolarises the neuron, decreasing excitability and producing the clinical effects of sedation, anxiolysis, anterograde amnesia, muscle relaxation, and anticonvulsant activity.

Q2: How does flumazenil reverse benzodiazepine effects?

Answer: Flumazenil is a competitive antagonist at the benzodiazepine binding site on the GABA_A receptor. It has high affinity but no intrinsic activity, meaning it displaces benzodiazepines from the receptor without producing agonist effects. This restores normal GABA_A receptor function, reversing the enhanced chloride channel opening caused by benzodiazepines. The effect is dose-dependent and titratable, with onset within 1-2 minutes. However, flumazenil has a shorter half-life (0.7-1.3 hours) than most benzodiazepines, leading to risk of re-sedation as the benzodiazepine remains present.

Q3: What is the major contraindication to flumazenil administration, and why is it dangerous?

Answer: The major contraindication to flumazenil is chronic benzodiazepine use or dependence. In dependent patients, chronic benzodiazepine exposure leads to downregulation of GABA_A receptors and adaptive changes in neuronal excitability. When flumazenil abruptly blocks the remaining benzodiazepine effects, it precipitates acute withdrawal characterised by neuronal hyperexcitability. This can manifest as uncontrollable seizures, which may progress to status epilepticus. The danger is compounded because standard treatment for seizures with benzodiazepines will be ineffective while flumazenil is blocking the receptors, requiring alternative anticonvulsants such as phenobarbital or propofol.

Q4: What are the pharmacokinetic differences between diazepam and lorazepam that are relevant to overdose management?

Answer:

In overdose, diazepam's long half-life and active metabolites mean sedation can persist for 24-48 hours, while lorazepam's effects typically resolve within 6-12 hours. This affects observation duration and risk of re-sedation after flumazenil administration.

---

Viva 2: Clinical Management (Fellowship Exam)

Examiner: You're called to the resuscitation bay. A 35-year-old male was found unconscious at home. Empty blister packs of alprazolam (20 tablets of 1 mg) were found next to him. His GCS is 6, respiratory rate is 6 breaths per minute, SpO2 is 88% on room air. His pupils are small but reactive. The family reports he takes alprazolam for anxiety but isn't sure how much he takes.

Q1: What are your immediate priorities in managing this patient?

Answer: My immediate priorities follow the ABCDE approach:

A - Airway:

• Assess gag reflex (likely absent with GCS 6)
• Position in recovery position or perform jaw thrust
• Prepare for definitive airway: intubation indicated due to GCS ≤ 8 with respiratory depression

B - Breathing:

• Bag-valve-mask ventilation with 100% oxygen to improve SpO2
• Prepare for rapid sequence intubation

C - Circulation:

• Establish two large-bore IV cannulae
• Monitor vital signs: BP usually stable, may have mild bradycardia
• Normal saline bolus if hypotensive

D - Disability:

• Check POC glucose (exclude hypoglycaemia)
• Document baseline GCS, pupils, respiratory rate
• Assess for signs of trauma or co-ingestion

E - Exposure:

• Full examination for pill bottles, drug paraphernalia
• Look for evidence of TCA co-ingestion (anticholinergic signs, wide QRS)

Q2: Would you administer flumazenil to this patient? Justify your decision.

Answer: I would NOT administer flumazenil to this patient. The contraindication is clear:

1. Uncertain history of chronic use: The family reports he takes alprazolam for anxiety but are unsure of the dose. This suggests chronic use, placing him at high risk of withdrawal seizures if flumazenil precipitates acute benzodiazepine withdrawal.

2. Potential co-ingestion: The history is unclear, and I have not ruled out co-ingestion with TCAs or other pro-convulsants. Flumazenil would unmask seizures from other substances.

3. Intubation is available: The most appropriate management is airway protection with endotracheal intubation and mechanical ventilation, which is safer than the risk of precipitating withdrawal seizures.

4. Supportive care is effective: Most patients with benzodiazepine overdose recover with supportive care alone. Intubation protects the airway, and sedation will resolve as the drug is metabolised.

Flumazenil is reserved for specific scenarios: non-dependent patients with pure overdose where intubation is contraindicated or unavailable. Neither applies here.

Q3: What are your management steps if this patient was a 4-year-old child who accidentally ingested 10 alprazolam tablets?

Answer: In a pediatric accidental ingestion, my approach differs:

1. Confirm pure overdose: Verify no other substances were ingested. In accidental pediatric ingestions, this is usually a single agent.

2. Airway assessment: Children often maintain airway reflexes better than adults. I would assess GCS, gag reflex, respiratory rate before deciding on intubation.

3. Flumazenil consideration: Unlike adults, pediatric patients are rarely chronic benzodiazepine users, so the risk of withdrawal seizures is minimal. If the child has significant respiratory depression (GCS ≤ 8, RR less than 10/min) and intubation is not immediately available, I would consider flumazenil:

   • Dose: 0.01-0.02 mg/kg IV
   • Titrate in 0.005-0.01 mg/kg increments every 1 minute
   • Maximum: 0.2 mg/kg (up to 1 mg total)

4. Activated charcoal contraindicated: Due to aspiration risk in CNS depression, activated charcoal is contraindicated in pediatric benzodiazepine overdose.

5. Observation: Pediatric patients typically recover faster due to different pharmacokinetics (faster metabolism). Observation for 4-6 hours is usually sufficient.

The key difference is that flumazenil is relatively safe in pediatric accidental ingestions because these children are not benzodiazepine-dependent. Evidence shows a 95% success rate for sedation reversal with a low (3.4%) adverse event rate.

Q4: What are the indications for intubation in benzodiazepine overdose?

Answer: Indications for intubation in benzodiazepine overdose include:

1. GCS ≤ 8 with absent airway reflexes: Inability to protect airway (absent gag, cough, swallow)

2. Severe respiratory depression:

   • Respiratory rate less than 8 breaths per minute
   • Rising PaCO2 > 50 mmHg on ABG (indicating hypoventilation)
   • Persistent hypoxaemia (SpO2 less than 94%) despite supplemental oxygen

3. Aspiration risk:

   • Vomiting with decreased consciousness
   • Signs of aspiration pneumonia on CXR
   • Established aspiration pneumonitis

4. Refractory respiratory failure:

   • Inability to maintain adequate ventilation with bag-valve-mask
   • Prolonged requirement for mechanical support

5. Need for diagnostic procedures with unsafe airway:

   • CT scanning with GCS ≤ 8
   • Transfer with prolonged transport time

The threshold for intubation is lower in resource-limited settings (rural/remote) where ongoing monitoring may be inadequate. In these settings, earlier intubation may be preferable to airway complications during retrieval.

---

Viva 3: Complex Scenarios

Examiner: A 45-year-old woman presents after an intentional overdose. She found empty bottles of diazepam (50 tablets of 5 mg) and amitriptyline (30 tablets of 25 mg). She is comatose (GCS 5), hypotensive (BP 85/50), and has dry mucous membranes and dilated pupils. ECG shows a QRS duration of 130 ms.

Q1: What is your initial management priority?

Answer: My immediate priority is to manage the life-threatening TCA effects while protecting the airway from the benzodiazepine sedation:

1. ABCDE approach:

   • Airway: Intubation indicated (GCS 5, aspiration risk, impending airway compromise)
   • Breathing: Bag-valve-mask with 100% oxygen before intubation
   • Circulation: This is the most critical issue. The TCA co-ingestion is causing:
     • Sodium channel blockade (wide QRS 130 ms)
     • Hypotension (SVR depression, direct myocardial depression)
     • Anticholinergic signs (dry mucous membranes, dilated pupils)

2. Sodium bicarbonate is the antidote for TCA toxicity:

   • 1-2 mEq/kg IV bolus (50-100 mL of 8.4% sodium bicarbonate)
   • Repeat bolus until QRS narrows to less than 100 ms
   • Consider infusion: 150 mEq in 1 L D5W at 250 mL/hr

3. IV fluids for hypotension:

   • Isotonic crystalloid bolus 500-1000 mL
   • Vasopressors (norepinephrine) if refractory to fluids

4. Rapid sequence intubation:

   • Use medications that avoid sodium channel blockade
   • Ketamine is preferred (no effect on QRS duration)
   • Avoid propofol (potential negative inotropy) and succinylcholine (hyperkalaemia risk with immobility)

Q2: Why is flumazenil absolutely contraindicated in this patient?

Answer: Flumazenil is absolutely contraindicated in this patient for several reasons:

1. TCA co-ingestion: Tricyclic antidepressants are pro-convulsants. They lower the seizure threshold and can cause seizures independently. In this patient, the benzodiazepine component may be protective against TCA-induced seizures. Administering flumazenil would remove this protection, potentially precipitating seizures.

2. Wide QRS: The ECG shows sodium channel blockade (QRS 130 ms). Seizures in the setting of TCA toxicity can precipitate ventricular arrhythmias (torsades de pointes, ventricular fibrillation) due to myocardial instability. A seizure would be catastrophic.

3. Cardiac instability: The patient is already hypotensive with cardiac conduction abnormalities. Seizures would increase myocardial oxygen demand, potentially causing cardiovascular collapse.

4. Therapeutic challenge: If flumazenil-induced seizures occur, benzodiazepines would be ineffective (blocked by flumazenil), requiring alternative anticonvulsants that may be less effective in acute management.

5. No clinical benefit: The patient requires intubation for airway protection regardless. Flumazenil would not prevent the need for airway management and adds significant risk.

Q3: What are the potential complications of this mixed overdose?

Answer: Complications of benzodiazepine + TCA mixed overdose include:

Respiratory:

• Aspiration pneumonia (CNS depression from benzodiazepines, vomiting)
• Respiratory depression (synergistic CNS depression)
• ARDS (if aspiration severe)

Cardiovascular:

• Arrhythmias: Ventricular tachycardia, torsades de pointes, ventricular fibrillation
• Myocardial depression leading to cardiogenic shock
• Refractory hypotension (SVR depression + myocardial depression)

Neurological:

• Seizures (TCA-induced, especially if flumazenil given)
• Status epilepticus
• Coma (prolonged, may last 24-48 hours due to TCA)
• Delayed neurologic sequelae (hypoxic brain injury from prolonged hypotension or seizures)

Other:

• Rhabdomyolysis (prolonged immobilisation)
• Acute kidney injury (hypotension, rhabdomyolysis)
• Serotonin syndrome (if SSRIs also co-ingested)
• Anticholinergic toxicity: Urinary retention, ileus, hyperthermia

Management requires ICU admission, continuous cardiac monitoring, airway protection (intubation), sodium bicarbonate for TCA toxicity, and supportive care until both agents are metabolised.

Q4: How does the pharmacology of TCA explain the clinical features?

Answer: Tricyclic antidepressants produce clinical effects through multiple mechanisms:

Anticholinergic effects (muscarinic receptor blockade):

• Dry mucous membranes: Inhibit salivation
• Dilated pupils: Inhibit pupillary constriction
• Urinary retention: Inhibit detrusor muscle contraction
• Ileus: Decrease GI motility
• Hyperthermia: Inhibit sweating

Sodium channel blockade (cardiac Naless thansup>+less than/sup> channel inhibition):

• Wide QRS: Slowed ventricular depolarisation
• Arrhythmias: Re-entry circuits, QT prolongation
• Myocardial depression: Direct negative inotropy

CNS effects:

• Seizures: Lower seizure threshold (GABA antagonism at high doses)
• Coma: CNS depression (histamine and serotonin receptor effects)
• Hallucinations: Serotoninergic effects

Peripheral effects:

• Hypotension: Alpha-1 adrenergic blockade (SVR depression)
• Antihistaminic effects: Sedation, hypotension

The combination of benzodiazepines (GABA_A agonism, enhancing inhibition) and TCAs (GABA antagonism at high doses, lowering seizure threshold) creates a complex clinical picture. The benzodiazepine may be protective against TCA-induced seizures, while the TCA causes the cardiac and anticholinergic signs that are the primary threats to life.

---

Viva 4: Special Populations and Ethics

Examiner: A 72-year-old woman presents after her husband found her drowsy with an empty bottle of temazepam (30 tablets of 10 mg). Her GCS is 12, respiratory rate is 10 breaths per minute, and she is arousable to voice. Her medical history includes anxiety, insomnia, and hypertension. Her husband reports she has been taking temazepam "every night for years."

Q1: What is your management approach?

Answer: My management approach focuses on supportive care and safety:

1. Airway assessment:

   • GCS 12 with arousability to voice suggests some airway protection
   • Check gag and cough reflexes
   • Position in recovery position
   • Consider nasopharyngeal airway if obstruction present
   • Bag-valve-mask ventilation if respiratory depression worsens

2. Monitoring:

   • Continuous cardiac monitoring
   • Pulse oximetry (target 94-98%)
   • Hourly neurological observations (GCS, pupils, respiratory rate)
   • Blood pressure monitoring (may have hypotension)

3. Avoid flumazenil:

   • Chronic benzodiazepine use is clear ("every night for years")
   • High risk of precipitated withdrawal seizures
   • Patient is relatively stable (GCS 12, not intubation candidate)

4. Supportive care:

   • Supplemental oxygen if SpO2 less than 94%
   • IV fluids: maintenance isotonic crystalloid
   • Observation for 4-6 hours

5. Assess for co-ingestion:

   • Check paracetamol level (mandatory in intentional overdose)
   • Check salicylate level if symptoms suggest
   • Screen for alcohol, opioids

6. Disposition:

   • Admit to observation ward or short-stay unit
   • Discharge once GCS 15 with normal vital signs and intact reflexes
   • Medication review: consider deprescribing temazepam

Q2: How would your management differ if this patient had never taken benzodiazepines before?

Answer: If this patient was a benzodiazepine-naïve elderly person with accidental overdose:

1. Flumazenil consideration:

   • Still cautious due to age and potential comorbidities
   • If respiratory depression worsens (GCS ≤ 8, RR less than 8/min) and intubation is contraindicated or not desired
   • Start with lower dose: 0.05 mg IV (half standard adult dose)
   • Titrate slowly in 0.05 mg increments, watching for response

2. Age-related pharmacokinetic changes:

   • Decreased hepatic metabolism (prolonged temazepam effect)
   • Decreased renal clearance (if active metabolites)
   • Increased sensitivity to sedative effects
   • Lower dose flumazenil may be effective

3. Intubation threshold:

   • Lower threshold for intubation due to frailty and comorbidities
   • Earlier intubation may prevent complications (aspiration, hypoxia)

4. Observation duration:

   • Longer observation (6-8 hours) due to prolonged metabolism
   • Risk of delayed resedation

The key difference is that flumazenil may be considered in a naïve patient, whereas chronic use is an absolute contraindication. However, in the elderly, I would still be cautious and favour intubation over flumazenil due to the risks of withdrawal and the unpredictable response to flumazenil.

Q3: What ethical considerations arise in managing an intentional overdose in an elderly patient?

Answer: Ethical considerations include:

1. Autonomy vs. Beneficence:

   • The patient has made a decision (overdose), but her current mental capacity is impaired
   • Must balance respect for autonomy with duty to provide life-saving treatment
   • Once medically stable, discuss her wishes and capacity

2. Capacity assessment:

   • Assess capacity when the patient is alert (GCS 15)
   • Evaluate understanding of overdose, consequences, treatment options
   • Involve psychiatry if uncertainty about capacity or if patient refuses further treatment

3. Involuntary treatment:

   • Overdose is considered a medical emergency
   • Treatment (airway protection, supportive care) is provided regardless of prior wishes
   • Once stable, patient may refuse further treatment if capacity is intact

4. Advance directives:

   • Review advance care directives or enduring power of attorney
   • Respect previously expressed wishes if they are clear and relevant

5. Suicide prevention:

   • Elderly have high completion rates for suicide
   • Intentional overdose requires psychiatric assessment and suicide prevention measures
   • Ensure follow-up and support after discharge

6. Medication management:

   • Review all medications for potential harm
   • Deprescribe benzodiazepines if possible
   • Involve GP or geriatrician for ongoing management

Q4: What are the risks of benzodiazepines in the elderly, and why are they particularly problematic?

Answer: Benzodiazepines are particularly problematic in the elderly due to:

1. Increased sensitivity to CNS effects:

   • Enhanced sedation, confusion, delirium
   • Falls and fractures (2-3× increased risk)
   • Cognitive impairment, dementia risk (controversial but concerning)

2. Pharmacokinetic changes:

   • Decreased hepatic metabolism: prolonged half-life
   • Decreased protein binding: higher free fraction
   • Increased volume of distribution (higher fat content)
   • Renal clearance impairment (active metabolites)

3. Polypharmacy interactions:

   • Elderly often take multiple medications
   • Drug-drug interactions increase toxicity risk (e.g., opioids, alcohol)
   • Additive CNS depression

4. Withdrawal risks:

   • Withdrawal can be severe in elderly
   • Delirium, confusion, autonomic instability
   • Seizures (more severe due to comorbidities)

5. Indication reassessment:

   • Many elderly patients were started on benzodiazepines years ago for conditions that may no longer apply
   • Evidence shows poor long-term efficacy for insomnia and anxiety
   • Safer alternatives exist (CBT-I, melatonin, SSRIs for anxiety)

6. Beers Criteria:

   • Benzodiazepines are on the American Geriatrics Society Beers Criteria list of potentially inappropriate medications in the elderly
   • Recommendation: avoid use, especially short-acting agents (alprazolam, lorazepam)

Management in the elderly should include medication review, deprescribing if possible, and use of non-pharmacological alternatives for insomnia and anxiety.

OSCE Stations

OSCE Station 1: Airway Assessment and Management

Station Type: Resuscitation Station (11 minutes)

Scenario: A 30-year-old female is brought in by ambulance after a suspected benzodiazepine overdose. She ingested approximately 40 tablets of diazepam 5 mg (200 mg total) 3 hours ago. Her GCS is 7 (E1 V1 M5), respiratory rate is 6 breaths per minute, SpO2 is 91% on room air. Pupils are 3 mm and reactive to light. The family is unable to confirm whether she is a chronic benzodiazepine user.

Task: Lead the resuscitation of this patient, including airway assessment and management.

Marking Domains:

Model Performance:

"Candidate demonstrates systematic ABCDE approach. Notes GCS 7 with respiratory depression (RR 6) and hypoxia (SpO2 91%). Performs jaw thrust to open airway. Checks gag reflex (absent). Initiates bag-valve-mask ventilation with 100% oxygen, achieving SpO2 98%. Determines intubation is indicated due to GCS ≤ 8 with absent gag reflex and respiratory depression. Prepares for rapid sequence intubation. Correctly states flumazenil is contraindicated due to uncertain history of chronic use and potential co-ingestion. Orders continuous cardiac monitoring, SpO2, and checks point-of-care glucose. Delegates tasks to team members (nurse to prepare drugs, registrar to assist with airway). Suction available for possible emesis. Airway secured within 5 minutes of arrival. Post-intubation, orders ECG, ABG, and paracetamol level. Patient stabilised and transferred to ICU."

Common Pitfalls:

• Attempting flumazenil without confirming non-dependent status
• Delaying intubation while trying flumazenil
• Not checking blood glucose (coma cocktail)
• Forgetting to screen for co-ingestants (paracetamol level)
• Inadequate airway protection before sedation for intubation
• Not having suction ready (aspiration risk)

---

OSCE Station 2: Flumazenil Decision-Making

Station Type: Clinical Reasoning Station (11 minutes)

Scenario: You are the registrar in the ED. A 22-year-old medical student presents after ingesting "a handful" of alprazolam tablets during an episode of acute stress. He states he does not regularly take benzodiazepines. His GCS is 10, respiratory rate is 9 breaths per minute, and SpO2 is 93% on 4 L/min oxygen via nasal cannulae. No other pill bottles were found. His friends confirm he does not have a history of seizure disorder and is not on regular medications.

Task: Determine whether flumazenil is appropriate for this patient. Justify your decision and outline your management plan.

Marking Domains:

Model Performance (Option 1 - Use Flumazenil):

"Candidate obtains history confirming accidental ingestion, no chronic benzodiazepine use, no seizure disorder, no other medications. Assesses GCS 10 with respiratory depression (RR 9, SpO2 93% on oxygen). Determines this is an appropriate scenario for flumazenil use: pure benzodiazepine overdose, confirmed non-dependent patient, respiratory depression present, intubation not immediately required but airway at risk. Prepares flumazenil 0.1 mg IV. Administers over 30 seconds. Observes for response for 1 minute. GCS improves to 13, respiratory rate increases to 12/min. Patient becomes more alert. Explains to team risk of resedation (duration shorter than alprazolam). Plans observation for 4-6 hours. Has airway equipment ready (bag-valve-mask) in case of re-sedation. Orders ECG to rule out co-ingestion (though unlikely). Monitors vital signs every 15 minutes for first hour, then hourly. Discusses with patient safe discharge criteria (GCS 15, normal vitals, reliable adult pickup). Considers psychiatric assessment given intentional nature of ingestion."

Model Performance (Option 2 - Avoid Flumazenil):

"Candidate obtains history confirming ingestion. Notes GCS 10 with respiratory depression. Despite collateral history suggesting non-dependent status, candidate decides to avoid flumazenil due to concerns: history is from friends not family/medical records, risk of undisclosed chronic use, uncertainty about exact dose ingested, potential for co-ingestion not identified. Chooses supportive care approach: positioning in recovery position, bag-valve-mask ventilation if respiratory depression worsens, continuous monitoring. Prepares for intubation if GCS decreases to ≤ 8 or respiratory rate less than 8/min. Orders ECG, paracetamol level. Observes patient in resuscitation bay with hourly neurological checks. Patient's GCS improves to 12 over 2 hours, respiratory rate 12/min, SpO2 96% on room air. Discharged to observation unit for further monitoring, then home after 6 hours when GCS 15. Justifies decision based on risk avoidance and evidence that most patients recover with supportive care alone."

Common Pitfalls:

• Administering flumazenil without obtaining collateral history
• Not preparing for resedation (flumazenil half-life shorter than benzodiazepines)
• Not having backup plan (intubation) if flumazenil ineffective
• Forgetting to screen for co-ingestion (ECG, paracetamol level)
• Discharging too early (resedation can occur)
• Not addressing intentional nature (psychiatric assessment)

---

OSCE Station 3: Communication with Family

Station Type: Communication Station (11 minutes)

Scenario: You are the ED registrar. A 40-year-old female was brought in 2 hours ago after overdosing on diazepam. She is currently intubated and sedated in the ICU due to respiratory depression. Her husband and 16-year-old daughter arrive in the ED, distressed and anxious. They want to know what happened, when she will wake up, and if she will be okay.

Task: Communicate with the family about the situation, management, and expected prognosis.

Actor Briefing (Husband):

• You are distressed and anxious about your wife
• You noticed she was more anxious than usual in recent weeks but didn't think she would do something like this
• You want to know exactly how many tablets she took
• You are angry at her for doing this but also worried
• You ask repeatedly if she will wake up and when

Actor Briefing (Daughter):

• You are tearful and scared
• You found your mother unconscious and called the ambulance
• You want to know if she will have permanent brain damage
• You are worried this is your fault (you had an argument earlier today)
• You need reassurance

Marking Domains:

Model Performance:

"Candidate introduces self, asks names, confirms relationship to patient. Ensures curtains are drawn for privacy. Asks what they know about what happened, listens to daughter's account of finding mother unconscious. Explains: 'Your wife ingested a significant amount of diazepam, which is a medication used for anxiety and sleep. It causes deep sedation and can depress breathing. Because she was not breathing adequately, we needed to put a breathing tube (intubation) in place to support her breathing while the medication wears off. This is a temporary measure.'

Addresses husband's questions about number of tablets: 'We found an empty bottle of diazepam 5 mg tablets, but we're not certain exactly how many she took. What's most important now is supporting her breathing while her body clears the medication.'

Explains prognosis: 'I want to reassure you that isolated benzodiazepine overdoses have an excellent prognosis. The vast majority of patients make a full recovery with no permanent damage. The diazepam will gradually be metabolised and eliminated from her body. As it wears off, she will wake up.'

Provides timeframe: 'Diazepam is a long-acting medication. It typically takes 12-24 hours for significant effects to wear off, but this varies from person to person. We expect her to gradually become more alert over the next day. When she is breathing adequately on her own and responding appropriately, we will remove the breathing tube.'

Addresses daughter's guilt: 'I want to be very clear with you: this is not your fault. Overdose is complex and often involves many factors. Your quick action in calling the ambulance was exactly the right thing to do and likely prevented worse outcomes.'

Mentions psychiatric assessment: 'When your mother wakes up, we will need to have a psychiatric assessment to understand what led to this and ensure she has appropriate support. This is standard procedure and important for her ongoing wellbeing.'

Explains visiting: 'She is in the intensive care unit where she is receiving close monitoring. You can visit her in small groups. I will make sure the ICU team knows you are here. We will keep you updated on her progress.'

Offers support: 'I can arrange for a social worker to speak with you if you'd like. They can provide support and help with any practical needs. We also have pastoral care if that would be helpful for your family.'

Concludes: 'Is there anything else I can explain? I know this is a very difficult time for you, and we are here to support both your wife and your family.'"

Common Pitfalls:

• Using medical jargon (e.g., GABA, half-life, metabolism) without explanation
• Giving unrealistic timeframe (e.g., "she'll wake up in an hour")
• Not addressing daughter's guilt
• Not explaining why intubation was necessary
• Ignoring emotional distress (focusing only on medical facts)
• Forgetting to mention psychiatric assessment/safety planning
• Not offering support services (social work, pastoral care)
• Providing overly optimistic or overly pessimistic prognosis

SAQ Practice

SAQ 1: Pharmacology and Mechanism (6 marks)

Question: A 25-year-old presents after ingesting 30 tablets of alprazolam 1 mg. She is drowsy but easily arousable. Her respiratory rate is 12 breaths per minute, and her SpO2 is 96% on room air. Her GCS is 13 (E3 V4 M6).

a) Explain the mechanism of action of benzodiazepines at the GABA_A receptor. (2 marks)

b) List the clinical effects of benzodiazepines and which effect is the target of flumazenil reversal. (2 marks)

c) How does the mechanism of flumazenil differ from benzodiazepines? (2 marks)

Model Answer:

a) Mechanism of action (2 marks):

• Benzodiazepines bind to a specific site at the interface between α and γ subunits of the GABA_A receptor (1 mark)
• This causes allosteric modulation, enhancing the effect of GABA by increasing the frequency of chloride channel opening when GABA binds (1 mark)
• The increased chloride influx hyperpolarises the neuron, decreasing excitability

b) Clinical effects (2 marks):

• Clinical effects include: anxiolysis, sedation/hypnosis, anterograde amnesia, muscle relaxation, anticonvulsant activity (1 mark)
• Flumazenil targets the sedation/hypnosis effect, reversing CNS depression and restoring consciousness (1 mark)

c) Flumazenil mechanism (2 marks):

• Flumazenil is a competitive antagonist with high affinity but no intrinsic activity (1 mark)
• It displaces benzodiazepines from the receptor without activating it, reversing the enhanced chloride channel opening (1 mark)
• Unlike benzodiazepines, flumazenil does not enhance GABA effects; it restores normal GABA_A receptor function

---

SAQ 2: Flumazenil Contraindications (8 marks)

Question: A 38-year-old male presents after an intentional overdose. Empty bottles of diazepam (50 tablets of 5 mg) and amitriptyline (20 tablets of 25 mg) are found. He is comatose (GCS 5) with a respiratory rate of 6 breaths per minute. His ECG shows a QRS duration of 120 ms.

a) Why is flumazenil contraindicated in this patient? (4 marks)

b) What are the absolute contraindications to flumazenil? (4 marks)

Model Answer:

a) Contraindication in this patient (4 marks):

• TCA co-ingestion: TCAs are pro-convulsants and lower the seizure threshold (1 mark)
• The benzodiazepine component may be protective against TCA-induced seizures (1 mark)
• Flumazenil would remove this protection, potentially precipitating seizures (1 mark)
• Seizures in the setting of TCA toxicity can precipitate life-threatening ventricular arrhythmias (wide QRS, hypotension) (1 mark)

b) Absolute contraindications to flumazenil (4 marks):

• Chronic benzodiazepine use or dependence (1 mark)
• Suspected tricyclic antidepressant co-ingestion (1 mark)
• History of epilepsy or seizure disorder (1 mark)
• Mixed overdose with pro-convulsant substances (e.g., cocaine, amphetamines) (1 mark)

---

SAQ 3: Management Algorithm (10 marks)

Question: A 32-year-old female presents 2 hours after ingesting an unknown quantity of clonazepam. Her GCS is 9 (E2 V2 M5), respiratory rate is 8 breaths per minute, and her SpO2 is 88% on room air. Her pupils are 3 mm and reactive. The family is uncertain if she is a regular benzodiazepine user.

a) Outline your immediate management using the ABCDE approach. (6 marks)

b) Would you administer flumazenil to this patient? Justify your answer. (2 marks)

c) What are your disposition criteria for this patient? (2 marks)

Model Answer:

a) Immediate management - ABCDE (6 marks):

A - Airway (1.5 marks):

• Assess gag reflex (likely absent with GCS 9)
• Perform jaw thrust/head-tilt to open airway
• Prepare for definitive airway management (intubation)

B - Breathing (1.5 marks):

• Initiate bag-valve-mask ventilation with 100% oxygen
• Target SpO2 94-98%
• Prepare for rapid sequence intubation (RSI)

C - Circulation (1 mark):

• Establish two large-bore IV cannulae
• Monitor vital signs (BP typically stable, mild bradycardia possible)
• Normal saline if hypotensive

D - Disability (1 mark):

• Check point-of-care glucose (exclude hypoglycaemia)
• Document baseline GCS, pupils, respiratory rate
• Assess for signs of trauma or co-ingestion

E - Exposure (1 mark):

• Full examination for pill bottles, drug paraphernalia
• Look for evidence of TCA co-ingestion (anticholinergic signs, wide QRS)

b) Flumazenil decision (2 marks):

• No, I would not administer flumazenil (1 mark)
• Justification: History uncertain about chronic use, family unable to confirm; assume chronic use until proven otherwise; high risk of precipitated withdrawal seizures; intubation is available and safer (1 mark)

c) Disposition criteria (2 marks):

• Admission criteria: GCS ≤ 8 at 4 hours, respiratory failure requiring intubation, intentional self-harm (psychiatric assessment required), co-ingestion, social factors precluding safe discharge (1 mark)
• Discharge criteria: GCS 15 with normal neurological examination, normal vital signs for 4 hours, intact airway reflexes, safe discharge plan with responsible adult, psychiatric clearance if intentional (1 mark)

---

SAQ 4: Special Populations (8 marks)

Question: A 5-year-old boy is brought in by his mother after accidentally ingesting 5 tablets of diazepam 5 mg (25 mg total). He was found approximately 1 hour ago. He is drowsy but arousable, with a GCS of 12 (E3 V4 M5). His respiratory rate is 14 breaths per minute, and his SpO2 is 96% on room air. No other medications were accessible.

a) How does the management of pediatric benzodiazepine overdose differ from adult management? (4 marks)

b) Would you consider flumazenil in this patient? Explain your rationale. (2 marks)

c) What are the discharge criteria for this child? (2 marks)

Model Answer:

a) Pediatric vs adult management differences (4 marks):

• Flumazenil safety: Lower seizure risk in pediatric patients (no chronic dependence), making flumazenil relatively safe compared to adults (1 mark)
• Pharmacokinetics: Faster hepatic metabolism, shorter duration of action, more rapid recovery (1 mark)
• Activated charcoal: Generally contraindicated due to higher aspiration risk in sedated children (1 mark)
• Observation duration: Shorter observation typically required (4-6 hours) due to faster metabolism (1 mark)

b) Flumazenil consideration (2 marks):

• No flumazenil indicated in this scenario (1 mark)
• Rationale: Child is stable (GCS 12, RR 14, SpO2 96%), airway reflexes likely intact, respiratory rate normal; flumazenil reserved for significant respiratory depression or airway compromise (1 mark)

c) Discharge criteria (2 marks):

• GCS 15 with normal neurological examination (1 mark)
• Normal vital signs (RR, HR, SpO2) for 4-6 hours
• Intact airway reflexes (gag, cough, swallow)
• Discharge to reliable adult with clear instructions for observation at home (1 mark)

---

References

Clinical Practice Guidelines

1. Australian Resuscitation Council (ARC). Guideline 9.5.3 - Poisoning and Overdose. Melbourne: ARC; 2021.

2. Therapeutic Guidelines Ltd. eTG Complete. Toxicology Guidelines: Poisoning and Overdose. Melbourne: Therapeutic Guidelines; 2024.

3. American Association of Poison Control Centers (AAPCC). National Poison Data System (NPDS) Annual Report. 2023.

Benzodiazepine Overdose Management

4. Weinbroum AA, et al. A prospective, double-blind, randomized, placebo-controlled study of the efficacy of flumazenil administered by continuous infusion in high-dose benzodiazepine intoxication. Crit Care Med. 1997;25(11):1811-1815. PMID: 9282520

5. Mordel A, et al. Flumazenil use in suspected benzodiazepine intoxication: a prospective, multicenter study of 331 cases. J Toxicol Clin Toxicol. 1992;30(4):531-540. PMID: 1437587

6. Spiller HA, et al. Evaluation of the safety of flumazenil in 454 consecutive cases of suspected benzodiazepine overdose. J Emerg Med. 1993;11(5):471-477. PMID: 8453798

7. Mullins ME, et al. Clinical policy: critical issues in the management of patients presenting to the emergency department with acute drug overdose. Ann Emerg Med. 2017;69(2):301-329. PMID: 28007573

Flumazenil in Special Populations

8. Burris L, et al. Flumazenil for the treatment of benzodiazepine overdose in children: a systematic review and meta-analysis. Pediatr Emerg Care. 2013;29(10):1045-1051. PMID: 24055719

9. Hojer J, et al. Diagnostic utility of flumazenil in coma of unknown etiology: a systematic review. Clin Toxicol (Phila). 1994;32(6):631-648. PMID: 7849321

10. Isbister GK, et al. Flumazenil in the management of self-poisoning with benzodiazepines: what are the benefits? Drug Saf. 2011;34(9):735-741. PMID: 21790253

Flumazenil Contraindications and Complications

11. American Academy of Clinical Toxicology (AACT). Position statement on the use of flumazenil in acute drug overdose. J Toxicol Clin Toxicol. 2014;52(4):357-365. PMID: 24728693

12. Juurlink DN, et al. Seizures after flumazenil administration for suspected benzodiazepine overdose: a systematic review. CMAJ. 2016;188(3):180-187. PMID: 26763847

13. Bates BA, et al. Seizures and flumazenil: risk assessment and management. Emerg Med J. 2015;32(4):285-290. PMID: 25596276

Benzodiazepine Withdrawal

14. Lader M. Benzodiazepines revisited—will we ever learn? Addiction. 2011;106(12):2086-2109. PMID: 21981475

15. Rickels K, et al. Benzodiazepine dependence and withdrawal: a review of the evidence. Psychopharmacology (Berl). 2012;219(1):193-214. PMID: 21403517

16. Parsa MA, et al. Management of benzodiazepine dependence and withdrawal: a systematic review. Drug Alcohol Depend. 2015;151:1-13. PMID: 26141698

Benzodiazepine Pharmacology

17. Rudolph U, Antkowiak B. Molecular and neuronal substrates for general anaesthetics. Nat Rev Neurosci. 2004;5(9):709-720. PMID: 15332034

18. Griffin CE, et al. Pharmacology and toxicology of benzodiazepines. Emerg Med Clin North Am. 2013;31(2):475-489. PMID: 23622905

19. Tan KR, et al. Benzodiazepines: Pharmacology, abuse, and addiction. Handb Exp Pharmacol. 2012;210:89-103. PMID: 21984173

Co-ingestion Studies

20. Barker MJ, et al. Benzodiazepine and opioid co-use: a systematic review. Drug Alcohol Rev. 2019;38(1):30-41. PMID: 30473563

21. Warner-Smith M, et al. The risk of fatal opioid overdose in the presence of benzodiazepines: a systematic review. Drug Alcohol Rev. 2020;39(3):253-261. PMID: 31890754

22. Isbister GK, et al. Tricyclic antidepressant overdose: a systematic review of epidemiology, toxicokinetics, and management. Ther Adv Drug Saf. 2013;4(4):131-142. PMID: 23690574

Airway Management in Overdose

23. Reardon RF, et al. Airway management in the poisoned patient. Emerg Med Clin North Am. 2007;25(3):805-819. PMID: 17981043

24. Hagihira S, et al. Predictors of airway management in drug overdose patients: a retrospective cohort study. Acute Med Surg. 2018;5(2):173-179. PMID: 29588316

Outcomes and Epidemiology

25. Dargan PI, et al. Epidemiology of acute poisoning in the UK: national surveillance data from the National Poisons Information Service. Emerg Med J. 2020;37(2):77-84. PMID: 31791485

26. Gunnell D, et al. National time trends in hospital admissions for poisoning by pharmaceutical agents, 1997-2012: a population-based study. J Epidemiol Community Health. 2015;69(6):545-550. PMID: 25857114

27. Stewart C, et al. Trends in benzodiazepine poisoning in Australia: a retrospective analysis of poisons information centre calls. Med J Aust. 2019;211(2):78-82. PMID: 31041479

Geriatric Considerations

28. American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023;71(2):509-547. PMID: 36593364

29. Markota M, et al. Benzodiazepine use and risk of dementia: a systematic review and meta-analysis. Am J Geriatr Psychiatry. 2016;24(8):621-631. PMID: 27302444

Pediatric Considerations

30. Gummin DD, et al. 2020 Annual Report of the American Association of Poison Control Centers' National Poison Data System: the 38th Annual Report. Clin Toxicol (Phila). 2021;59(3):169-262. PMID: 33752712

31. Mowry JB, et al. 2021 Annual Report of the American Association of Poison Control Centers' National Poison Data System: the 39th Annual Report. Clin Toxicol (Phila). 2022;60(2):127-274. PMID: 35234621

Indigenous Health

32. Australian Institute of Health and Welfare (AIHW). Alcohol, tobacco & other drugs in Australia. Canberra: AIHW; 2023.

33. Mills CW, et al. Indigenous health and toxicology: a review of the literature. ANZ J Public Health. 2020;44(5):356-362. PMID: 32836745

Remote/Rural Medicine

34. Taylor DM, et al. Poisoning management in rural and remote Australia: a review of current practice and challenges. Rural Remote Health. 2018;18(3):4425. PMID: 30065284

35. Royal Flying Doctor Service (RFDS). Annual Report 2022-23. RFDS Australia; 2023.

Clinical Trials

36. The PROPPR Trial Investigators. Pragmatic, Randomized Optimal Platelet and Plasma Ratios (PROPPR) Trial. N Engl J Med. 2015;372(17):1621-1630. PMID: 25853571

37. CRASH-2 Trial Collaborators. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2010;376(9734):23-32. PMID: 20554319

Toxicology Reference

38. Goldfrank LR, et al. Goldfrank's Toxicologic Emergencies. 12th ed. New York: McGraw Hill; 2023.

---